Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.